One Year’s Treatment with the Glucagon-Like Peptide 1 Receptor Agonist Liraglutide Decreases Hepatic Fat Content in Women with Nonalcoholic Fatty Liver Disease and Prior Gestational Diabetes Mellitus in a Randomized, Placebo-Controlled Trial

Prior gestational diabetes mellitus (pGDM) is associated with increased risk of nonalcoholic fatty liver disease (NAFLD). Treatment with glucagon-like peptide 1 (GLP-1) receptor agonists has shown beneficial effects in NAFLD patients. We evaluated the effect of the GLP-1 analogue liraglutide on NAFL...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:J Clin Med
Autores principales: Vedtofte, Louise, Bahne, Emilie, Foghsgaard, Signe, Bagger, Jonatan I., Andreasen, Camilla, Strandberg, Charlotte, Gørtz, Peter M., Holst, Jens J., Grønbæk, Henning, Svare, Jens A., Clausen, Tine D., Mathiesen, Elisabeth R., Damm, Peter, Gluud, Lise L., Knop, Filip K., Vilsbøll, Tina
Formato: Artigo
Lenguaje:Inglês
Publicado: MDPI 2020
Materias:
Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC7601647/
https://ncbi.nlm.nih.gov/pubmed/33036179
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/jcm9103213
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares